Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review
Zobair M. Younossi, Kathleen E. Corey, Joseph K. Lim
Gastroenterology (2020) Vol. 160, Iss. 3, pp. 912-918
Closed Access | Times Cited: 362

Showing 1-25 of 362 citing articles:

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
Zobair M. Younossi, Pegah Golabi, James M. Paik, et al.
Hepatology (2023) Vol. 77, Iss. 4, pp. 1335-1347
Open Access | Times Cited: 1433
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 669
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Michael H. Le, Yee Hui Yeo, Xiaohe Li, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 12, pp. 2809-2817.e28
Closed Access | Times Cited: 486
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal, Jay H. Shubrook, Leon A. Adams, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1657-1669
Open Access | Times Cited: 378
Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai–Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 299
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 4, pp. 367-378
Open Access | Times Cited: 171
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
Zobair M. Younossi, Linda Henry
JHEP Reports (2021) Vol. 3, Iss. 4, pp. 100305-100305
Open Access | Times Cited: 163
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 154
Lifestyle interventions in nonalcoholic fatty liver disease
Zobair M. Younossi, Shira Zelber‐Sagi, Linda Henry, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 11, pp. 708-722
Closed Access | Times Cited: 138
Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease
Yuanqiang Ma, Gyurim Lee, Suyoung Heo, et al.
Antioxidants (2021) Vol. 11, Iss. 1, pp. 91-91
Open Access | Times Cited: 134
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?
Zobair M. Younossi, James M. Paik, Reem Q. Al Shabeeb, et al.
Hepatology (2022) Vol. 76, Iss. 5, pp. 1423-1437
Closed Access | Times Cited: 130
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei‐Chuan Lee, Pei-Shan Wu, Han‐Chieh Lin
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. 1, pp. 77-98
Open Access | Times Cited: 113
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 100
Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China
Sailimai Man, Yuhan Deng, Yuan Ma, et al.
Gastroenterology (2023) Vol. 165, Iss. 4, pp. 1025-1040
Open Access | Times Cited: 90
The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
James M. Paik, Linda Henry, Youssef Younossi, et al.
Hepatology Communications (2023) Vol. 7, Iss. 10
Open Access | Times Cited: 85
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 78
Associations between life’s essential 8 and non-alcoholic fatty liver disease among US adults
Lili Wang, Jiayi Yi, Xinli Guo, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 72
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
Andrea Boccatonda, Lorenzo Andreetto, Damiano D’Ardes, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 883-883
Open Access | Times Cited: 65
Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis
Federico Ravaioli, Elton Dajti, Alessandro Mantovani, et al.
Gut (2023) Vol. 72, Iss. 7, pp. 1399-1409
Closed Access | Times Cited: 52
Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Xunzhe Yin, Xiangyu Guo, Zuojia Liu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2844-2844
Open Access | Times Cited: 47
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang‐Chin Huang, Chun‐Jen Liu
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 320-331
Open Access | Times Cited: 46
Therapeutic management of metabolic dysfunction associated steatotic liver disease
Jing Zeng, Jian‐Gao Fan, Sven Francque
United European Gastroenterology Journal (2024) Vol. 12, Iss. 2, pp. 177-186
Open Access | Times Cited: 38
Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries
Ehsan Amini‐Salehi, Negin Letafatkar, Naeim Norouzi, et al.
Archives of Medical Research (2024) Vol. 55, Iss. 6, pp. 103043-103043
Closed Access | Times Cited: 37
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus
Xufen Zeng, Krista A Varady, Xiangdong Wang, et al.
Metabolism (2024) Vol. 161, pp. 156028-156028
Closed Access | Times Cited: 25
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri
The Lancet Diabetes & Endocrinology (2024)
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top